CD8+ T Cells Contribute to Lung Cancer Progression in a PD-1 Dependent Fashion Stephanie Chang, Saeed Arefanian, Ryuji Higashikubo, Daniel Kreisel, Andrew.

Slides:

Advertisements

Similar presentations

The Journal of Immunology, 2013 March 27; 190: , IF=5.52

Advertisements

Tumor Immunology (I): Cancer Immunosurveillance & Immunoediting Masoud H. Manjili Department of Microbiology & Immunology Goodwin Research Building-286.

118/2/2015 Cancer & the Immune System Hugh B. Fackrell.

Tumor Immunology: Definitions: -Tumor (neoplasm): unchecked cellular growth. -Two types: 1-Benign: controlled tumor. 2-Malignant: uncontrolled tumor. -Malignant.

Chapter 19 Cancer and the Immune System Dr. Capers.

What Is Cancer? The Cancer Process Taken from:. Quick review… What is the cell cycle? Hmmm….what regulates/controls the cell cycle and tells each cell.

Cancer immunology and immunotherapy. First an aside  Oncogenes and tumor suppressor genes.  Definitions anyone?  Oncogene –  Tumor suppressor gene.

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Chapter 21 Cancer and the Immune System Dr. Capers

Powerpoint Templates Page 1 Powerpoint Templates Gene therapy for melanoma By Mohammed razeeth.S.

Cancer 101: A Cancer Education and Training Program for American Indians & Alaska Natives Cancer 101: A Cancer Education and Training Program for American.

Ribosomal Dysfunction Results in an Immunologic Susceptibility to Lung Cancer Stephanie Chang MD, Ryuji Higashikubo PhD, Saeed Arefanian MD, Andrew Gelman.

Host Defense Against Tumors (Tumor Immunity)

PHL 472 Chemical Carcinogens Abdelkader Ashour, Ph.D. 2 nd Lecture.

 What is cancer?  What could happen in mitosis or meiosis that could cause cancer?  What environmental factors could cause cancer?

Immunological tolerance and immune regulation -- 1

Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014

The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.

Bijoy Telivala, MD Advances in Immunotherapy Bijoy Telivala, MD

Cancer and the Immune System

Objectives Introduction Ags expressed by cancer cells

PD-L1 Expression in Metastatic Cutaneous Squamous Cell Carcinomas Nathaniel A. Slater, MD1, James Tidwell, MD2, George Sonnier, MD2, Paul Googe, MD1,3.

Mechanisms of T Cell Tolerance

Karyotyping Cancer.

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Table of Contents Section 1 Control of Gene Expression

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Tumor Immunity: Exploring the Role of a Checkpoint

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 17, Issue 4, Pages (October 2016)

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Nat. Rev. Rheumatol. doi: /nrrheum

Targets for immunotherapy of liver cancer

Preview Chapter 11 Multiple Choice Short Response Extended Response

Robert J Korst, MD, Ronald G Crystal, MD

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma Robert.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Nat. Rev. Endocrinol. doi: /nrendo

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Nat. Rev. Urol. doi: /nrurol

Jason M. Gauthier, MD, Ruben G. Nava, MD, Daniel Kreisel, MD, PhD

Daniel Kreisel, MD, PhD, Alexander S

Intro to Cancer.

Predictors of Survival After Operation Among Patients With Large Cell Neuroendocrine Carcinoma of the Lung Florian Eichhorn, MD, Hendrik Dienemann, MD,

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system Eric S Lambright, MD, David J Caparrelli, MD, Abbas E.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Treatment of Malignant Pleural Effusion: A Cost-Effectiveness Analysis

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Who should decide margin length in pulmonary excision of lung cancer?

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Presentation transcript:

CD8+ T Cells Contribute to Lung Cancer Progression in a PD-1 Dependent Fashion Stephanie Chang, Saeed Arefanian, Ryuji Higashikubo, Daniel Kreisel, Andrew Gelman, Alexander S. Krupnick Division of Cardiothoracic Surgery

CD8+ Memory Cells Current strategies for immunotherapy focus on activation and transfer of CD8+ cytotoxic T lymphocytes

Data from our lab

Higher Sarcoma in CD8-/- mice B6B6 CD8-/- 3-Methylcholantherene injection in flank B6B6 CD8-/-

Lower Lung Cancer Incidence in CD8-/- mice Urethane induction B6B6 CD8-/-

B6B6 CD8-/ B16 melanoma expressing ovalbumin

B6B6 CD8-/ Lewis Lung Carcinoma, B16 melanoma, expressing ovalbumin

unlike the case for most malignancies CD8 + T cells contribute to tolerance induction and more rapid growth of lung cancer this process is specific to lung cancer tumor cells themselves and not necessarily the lung environment since CD8 + T cell accelerated growth of lung cancer occurs even after injection of cell lines into the flank

Immunologic Phenotype

Tolerogenic role of PD-1/PD-L1 PD-1 blocking Ab (RMP1-14) ovalbumin expressing LLC cell line ns

Immunoregulation of lung cancer is unique among solid tumors Just because an immunotherapy works in another cancer does not mean it will work in lung cancer Unlike melanoma, lung cancer has a simple “co- stimulatory phenotype” of MHC Class I and PD-L1 Reversal of “CD8+ T suppressor cells” may explain the overwhelming success of PD-1/PDL-1 blockade in lung cancer The nature/identity of “CD8+ suppressor T cells” is still being explored in our laboratoryConclusion

Acknowledgements Thoracic Immunology Lab Alexander S. Krupnick, MD Daniel Kreisel, MD, PhD Andrew E. Gelman, PhD Stephanie Chang, MD Ryuji Higashikubo, PhD WenJun Li, MD Kelsey Toth Jihong Zhu Reza Ghasemi, PhD Jim Hsiao, PhD



B6B6 CD8-/ Lewis Lung Carcinoma, B16 melanoma, EG7 Lymphoma expressing ovalbumin